Digitally different solutions that offer lasting treatment for insomnia and anxiety

As two of the most common conditions affecting 80% of people living with mental illness, insomnia and anxiety are costly. Those struggling with comorbid insomnia average 79% higher healthcare costs2, and anxiety disorders are one of the top five costliest disease categories.3

Big Health is on a mission to cut costs and increase member engagement through our digital treatments Sleepio® and Daylight®.

Recommended as the first line of care in several clinical guidelines,4 our digital treatments use techniques developed by our industry-leading cognitive behavioral therapists to achieve remission of insomnia disorder and generalized anxiety disorder.6

In a clinical trial

of participants using Sleepio showed clinical improvement in insomnia7

of participants using Daylight showed clinical improvement in anxiety8

Effective treatments, lower utilization of costly services. Sleepio use demonstrated:

Comprehensive treatment for all, offered with:

  • Seamless billing – Billed pay-per-use with clinical performance guarantees

  • Extended capacity – Appeals to and engages hard-to-reach members

  • Compliance – Supports ERISA compliance with the Mental Health Parity and Addiction Equity Act

Use our interactive tool to evaluate and measure the impact of your current treatment options.

Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy.


  2. Stewart et al.(2016).

  3. Ruscio et al.(2007).

  4. Qaseem et al. (2016). Annals of Internal Medicine;

  5. Espie et al. (2012). Sleep.

  6. Carl et al. (2020). Depression & Anxiety.

  7. Espie et al. (2012). Sleep.

  8. Carl et al. (2020). Depression & Anxiety.

  9. Miller et al. (2020). A health economic evaluation of Sleepio at a Fortune 500 company. White paper. *This is a total estimate that is based on statistically significant and non-significant reductions in costs across categories, thus the exact figure would require confirmation in further research with a larger sample size.